Author: Staff

Joy and Boldness in Drug Development – with Paul Lammers

Posted on by Staff

Join us in this episode as we talk with Paul Lammers, CEO of Triumvira Immunologics, a clinical-stage biopharmaceutical company focusing on developing T cell therapies for cancer treatment. Born in the Netherlands and now an American citizen, Lammers’ early life shaped his views on being bold and making connections with people a priority. He shares his insights on crucial but often neglected topics in life science leadership, while also revealing his joy as a father to three grown daughters and a grandfather.

We discuss the importance of transparent and open communication between leaders and employees, especially during times of change or uncertainty. Lammers also shares his thoughts on the challenges of balancing innovation and risk with regulatory and financial constraints. Additionally, we delve into the significance of investing in talent development and creating opportunities for employees to learn and grow, both for their own advancement and the success of the organization. Tune in to learn from Paul Lammers’ experiences and gain insights into effective leadership strategies in the biotech industry.

Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting

Posted on by Staff

AUSTIN, Texas and HAMILTON, ON and SOUTH SAN FRANCISCO, Calif., April 18, 2023 /PRNewswire/ — Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics, today announced the details of the Company’s presentation at the 2023 AACR Annual Meeting on its lead asset, TAC01-HER2, for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors. The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 (NCT04727151) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Presentation details:

Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors

Authors: Ecaterina E. Dumbrava, MD, Daniel Olson, MD, Samuel Saibil, MD, Brooke Pieke, Mridula A. George, MD, Riemke Bouvier, Kelly Gruber, Kara Moss, Nathan Ternus, Maria Apostolopoulou, Deyaa Adib, MD, and Benjamin L. Schlechter, MD.

A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors

Posted on by Staff

INTRODUCTION

• The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the re-direction of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex, with the goal to elicit a safe and durable anti-tumor response. In preclinical models, TAC-engineered T cells effectively eradicate tumor cells in vitro and in vivo without toxicities typically associated with engineered T cell products. TAC01-HER2 is an autologous T-cell product comprising T cells expressing the HER2 TAC, which specifically recognize HER2+ cells.

• TACTIC-2 (NCT04727151) is an open-label, multicenter phase I/II study that aims to establish safety, maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), pharmacokinetic profile, and efficacy of TAC01-HER2 in patients with HER2-positive solid tumors by immunohistochemistry that are 1+, 2+, or 3+ (i.e. breast, lung, pancreatic, colorectal, gastric, endometrial, ovarian, and others) whom have progressed on prior anti-cancer therapies.

• We present updated preliminary data from Cohorts 1-4 (19 participants) that highlights safety and efficacy data; the study further elucidates potential therapeutic impact to patients with HER2 overexpressed solid tumors.

View/Download Poster

Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors

Posted on by Staff

Background

The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit a safe and durable anti-tumor response. TAC01-HER2, a 􀈈rst-inclass TAC T product targeting HER2 (ERBB2), has entered a Phase I/II clinical trial in patients with HER2-positive solid tumors. Here, we characterized the TAC T cell phenotypes and anti-tumor activity of TAC01-HER2 manufactured using leukocytes from Phase I/II patients in nonclinical in vitro and in vivo assays.

View/Download Poster

Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors

Posted on by Staff

Background

The T cell antigen coupler (TAC) is a novel, proprietary chimeric receptor that facilitates the redirection of T cells to tumor cells, and activates T cells by co-opting the endogenous T cell receptor complex with the goal to elicit safe and durable anti-tumor responses. TAC01-HER2, a 􀈈rst-in-class, autologous TAC T cell product targeting HER2 (ERBB2), has entered a phase I/II clinical trial in patients with HER2-positive solid tumors. Here, we describe the development of an allogeneic HER2-TAC T cell product based on Vγ9Vδ2 (γδ) T cells which belong to a subset of T cells that recognize target cells in a human leukocyte antigen (HLA) independent manner. Thus, γδ T cells do not cause GvHD and have the potential for allogeneic cell therapy applications.

View/Download Poster

Engineering Better Cell Therapies for Cancers

Posted on by Staff

Cell therapies are revolutionizing the way cancers are treated, but existing cell therapies have their limits. They have been more successful at treating hematologic tumors than solid tumors, and they can sometimes cause serious side effects, such as the destruction of antibodies or what’s known as cytokine storms in which the immune system gets over-revved and attacks healthy cells. Triumvira Immunologics is developing autologous and allogeneic T-Cell therapies that it believes can address the limitations of existing cell therapies and be used to treat both liquid and solid tumors.

We spoke to Paul Lammers, CEO of Triumvira, about the company’s platform technology, why it’s robust and versatile, and why its lead indication is for cancer where effective treatments already exist.

First in Human Episode #25 featuring Dr. Paul Lammers

Posted on by Staff

For episode 25, we sit down with Dr. Paul Lammers, CEO of Triumvira Immunologics. Stay tuned to learn why having multiple programs in clinical trials can provide a safety net should one program fail and how it adds additional value for investors. First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials.

Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder & guest host Co-Founder, Andrew Brackin.

On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions

Posted on by Staff

Join us for the third session in Lumanity’s New Cancer Progress Webinar series, “On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling With Lofty Expectations and Challenging Market Conditions,” on April 26th at 1:00pm ET moderated by Joel Sandler, Ph.D..

Hear from Mike DeRidder, Ajla Hrle, Michael Kalos, and Paul Lammers as they discuss implications and strategic considerations for companies grappling with skepticism from partners, investors, clinical/regulatory, and commercial perspectives.

JPM Highlights: What’s Next in ImmunoOncology

Posted on by Staff

In this episode, we talk with our panel about updates their company gave at the recent JP Morgan Healthcare Conference that took place earlier this year. This once-yearly conference is the epicenter for biotech deal-making and groundbreaking data releases.

Dr. Robert Ross is the Chief Executive Officer of Surface Oncology. Surface Oncology’s mission is to deliver transformative outcomes for people with cancer by breaking through the frontiers of immuno-oncology research. Before becoming CEO, Rob served as Chief Medical Officer at Surface. Prior to joining Surface, he led several programs in hematology and oncology at Bluebird Bio, including the anti-BCMA CAR T cell therapy program. Rob received his MD from Columbia University and has received extensive training in hematology and oncology at top institutions including the University of California San Francisco, Dana Farber, and Mass General Hospital.

Dr. Paul Lammers is the Chief Executive Officer of Triumvira Immunologics. Triumvira is leveraging its proprietary T-cell antigen coupling technology to enhance engineered cell therapy to target solid tumors. Paul has a rich background in biotech management, having served as President & CEO at Mirna Therapeutics and Chief Medical Officer and Head of US Product Development for EMD Serono. Paul received his MD from Radboud University in the Netherlands.

Hosted by Joe Varriale.